SG false 0001631574 0001631574 2026-11-12 2026-11-12
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2026

 

 

WAVE LIFE SCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-37627   42-2115035

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

733 Concord Avenue  
Cambridge, MA   02138
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 949-2900

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

symbol

 

Name of each exchange
on which registered

Common stock, $0.001 par value per share   WVE   The Nasdaq Global Market

 

 
 


Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e) On November 12, 2026, the stockholders of Wave Life Sciences, Inc. (the “Company”) approved an amendment to the Company’s Amended and Restated 2021 Equity Incentive Plan (the “Amended 2021 Equity Incentive Plan”), that increases the total number of shares of common stock authorized for issuance of awards under the Amended 2021 Equity Incentive Plan by 11,000,000 shares.

A detailed summary of the material features of the Amended 2021 Equity Incentive Plan is set forth in the Company’s definitive proxy statement for its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) filed with the Securities and Exchange Commission on October 14, 2026 (the “Proxy Statement”). That summary and the foregoing description are qualified in their entirety by reference to the text of the Amended 2021 Equity Incentive Plan, which is filed as Exhibit 10.1 hereto and incorporated herein by reference.

 

Item 5.07

Submission of Matters to a Vote of Security Holders.

 

(a)

On November 12, 2026, the Company held its Annual Meeting. Of the 197,228,058 shares of common stock issued and outstanding and eligible to vote as of the record date of October 8, 2026, a quorum of 166,197,073 shares of the Company’s voting capital stock, or 84%, of the eligible shares, was present in person or represented by proxy at the Annual Meeting.

 

(b)

The following actions were taken at the Annual Meeting, all of which are described in the Proxy Statement. The final voting results for each of the proposals voted upon at the Annual Meeting are set forth below.

Proposal 1 (a) – (i)- Stockholders re-elected nine of the Company’s existing directors to the Board of Directors to serve until the Company’s 2027 Annual Meeting of Stockholders and until their successor is duly elected and qualified, with the final votes cast as follows:

 

Board of Directors Nominee

   For      Withheld      Broker Non-
Vote
 

Paul B. Bolno, M.D., MBA

     140,320,706        2,498,241        23,378,126  

Mark H.N. Corrigan, M.D.

     139,187,432        3,631,515        23,378,126  

Christian Henry

     138,951,889        3,867,058        23,378,126  

Peter Kolchinsky, Ph.D.

     139,705,896        3,113,051        23,378,126  

Adrian Rawcliffe

     139,533,204        3,285,743        23,378,126  

Ken Takanashi

     120,135,906        22,683,041        23,378,126  

Aik Na Tan

     141,885,925        933,022        23,378,126  

Gregory L. Verdine, Ph.D.

     136,860,899        5,958,048        23,378,126  

Heidi L. Wagner, J.D.

     135,182,414        7,636,533        23,378,126  

Proposal 2- Stockholders approved the ratification of the appointment KPMG LLP to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2026, with the final votes cast as follows:

 

For

 

Against

 

Abstain

 

Broker Non-

Vote

165,767,838   338,795   90,440   0

Proposal 3- Stockholders approved the amendment to the Company’s Amended and Restated 2021 Equity Incentive Plan, as amended, in the manner and on the basis set forth in the Proxy Statement, with the final votes cast as follows:

 

For

 

Against

 

Abstain

 

Broker Non-

Vote

119,800,336   22,936,097   82,514   23,378,126

Proposal 4- Stockholders approved on a non-binding, advisory basis only, the compensation of the Company’s named executive officers, in the manner and on the basis set forth described in the Proxy Statement, with the final votes cast as follows:

 

For

 

Against

 

Abstain

 

Broker Non-Vote

133,800,043   8,866,314   152,590   23,378,126


Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit No.    Description
10.1+    Amended and Restated 2021 Equity Incentive Plan, as amended
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

+

Indicates management contract or compensatory plan or arrangement.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

WAVE LIFE SCIENCES, INC.
By:  

/s/ Paul B. Bolno, M.D.

  Paul B. Bolno, M.D.
  President and Chief Executive Officer

Date: November 18, 2026